Bausch Health's Canadian Subsidiary Lists PrOKEDI Dosages in RAMQ Formulary

Bausch Health Canada has listed the 75mg and 100mg dosages of its schizophrenia treatment, PrOKEDI, in Quebec’s public drug formulary (RAMQ). This marks a key step toward reimbursement for the medication in the province. The company previously secured a Letter of Intent with pCPA and plans to continue negotiations with other provinces.

By Muhammad Ali Khalid Sun, July 12, 2026 at 8:21 PM GMT+3 2 min read · Yahoo Finance · July 12, 2026, 17:21 UTC

Tickers: $BHC

Topics: Healthcare Access Pharmaceutical Regulatory Approval

Read the full article at Yahoo Finance

More World news

Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC